SCHEMBL57295

SCHEMBL57295

CC(Br)c1cccc2c1C(=O)NC2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
GAA P10253 1/20 0.45
GSK3B P49841 2/20 0.43
CASP3 P42574 5/20 0.42
CASP7 P55210 3/20 0.42
CASP2 P42575 2/20 0.42
CASP6 P55212 2/20 0.42
CASP8 Q14790 2/20 0.42
PARP1 P09874 5/20 0.41
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.35
RGS12 O14924 1/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166123 0.85 HPGD (0.47) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2824441 0.82 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2247260 0.81 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL3908443 0.79 GSK3B (0.48) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL4336651 0.79 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL10925239 0.79 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL8356651 0.79 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL1256987 0.79 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2820121 0.79 HPGD (0.45) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL3351153 0.78 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313675-A1 Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation NORTHWESTERN UNIVERSITY 2025-10-09 US disclosed
US-12162997-B2 Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation NORTHWESTERN UNIVERSITY (US) 2024-12-10 US disclosed
CN-113365984-B LOX inhibitors 癌症研究协会皇家癌症医院 2024-10-15 CN disclosed
US-20220017516-A1 LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-01-20 US disclosed
US-20220002502-A1 Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation NATIONAL SCIENCE FOUNDATION 2022-01-06 US disclosed
EP-3880664-A1 LOX INHIBITORS The Institute of Cancer Research: Royal Cancer Hospital (GB) 2021-09-22 EP disclosed
US-11124612-B2 Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation NORTHWESTERN UNIVERSITY (US) 2021-09-21 US disclosed
CN-113365984-A LOX inhibitors 癌症研究协会皇家癌症医院 2021-09-07 CN disclosed
CN-109641891-B Novel compounds and methods 维罗纳制药公司 2021-05-04 CN disclosed
US-20200255603-A1 Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation NATIONAL SCIENCE FOUNDATION 2020-08-13 US disclosed
US-5216150-A Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor Hidaka, Hiroyoshi (JP) 1993-06-01 US disclosed
US-5081246-A Isoquinolino sulfonamino derivatives Hidaka, Hiroyoshi (JP) 1992-01-14 US disclosed
CN-1044098-A Compounds with vascular smooth muscle relaxing activity HIDAKA HIROYOSHI (JP) 1990-07-25 CN disclosed
US-4908365-A Pharmaceuticals SOCIETE ANONYME (FR) 1990-03-13 US disclosed
US-4673684-A Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient TERUMO CORPORATION (JP) 1987-06-16 US disclosed
US-4604390-A FUNGICIDES, ANTITUMOR AGENTS WARNER-LAMBERT COMPANY (US) 1986-08-05 US disclosed
EP-0157420-A2 Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) 1985-10-09 EP disclosed
US-4542145-A Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides AMERICAN CYANAMID COMPANY (US) 1985-09-17 US disclosed
US-4539416-A Processes for making thioalkyl carboxamides and amines THE DOW CHEMICAL COMPANY (US) 1985-09-03 US disclosed
EP-0042440-B1 FIRE RETARDANT ORGANIC HIGH MOLECULAR COMPOSITION ACOME, SOCIETE COOPERATIVE DE TRAVAILLEURS (FR) 1985-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017516-A1 LOX INHIBITORS LOXL1, LOX, LOXL2 KDM4E 849/4885ALDH1A1 122/4885HPGD 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.